Ragweed Allergy – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Ragweed Allergy – Pipeline Review, H2 2016’, provides an overview of the Ragweed Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ragweed Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ragweed Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Ragweed Allergy

The report reviews pipeline therapeutics for Ragweed Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ragweed Allergy therapeutics and enlists all their major and minor projects

The report assesses Ragweed Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ragweed Allergy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ragweed Allergy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ragweed Allergy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Anergis SA

Biomay AG

Circassia Pharmaceuticals Plc

Immunomic Therapeutics, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Ragweed Allergy Overview 6

Therapeutics Development 7

Pipeline Products for Ragweed Allergy - Overview 7

Ragweed Allergy - Therapeutics under Development by Companies 8

Ragweed Allergy - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Unknown Stage Products 11

Ragweed Allergy - Products under Development by Companies 12

Ragweed Allergy - Companies Involved in Therapeutics Development 13

Anergis SA 13

Biomay AG 14

Circassia Pharmaceuticals Plc 15

Immunomic Therapeutics, Inc. 16

Ragweed Allergy - Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Drug Profiles 23

AllerR - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

BM-34 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Multi-LAMP-Vax - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

PL-101 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Vaccine for Asthma and Ragweed-Induced Rhinoconjunctivitis - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Ragweed Allergy - Dormant Projects 30

Ragweed Allergy - Discontinued Products 31

Ragweed Allergy - Product Development Milestones 32

Featured News & Press Releases 32

Dec 19, 2014: Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR 32

Dec 08, 2014: Circassia Announces Top-Line Results from Ragweed Allergy Treatment Phase IIb Chamber Study 32

Feb 21, 2013: Anergis To Present Preclinical Data On Ragweed Allergy Vaccine Candidate AllerR At AAAAI 2013 Annual Meeting 33

Jun 14, 2012: Anergis Reaches Several Preclinical Development Milestones With Ragweed Pollen Vaccine 34

Mar 07, 2012: Circassia’s Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results 35

Jan 19, 2012: Circassia Receives European Patent For Its Ragweed Allergy T-Cell Vaccine 35

Appendix 36

Methodology 36

Coverage 36

Secondary Research 36

Primary Research 36

Expert Panel Validation 36

Contact Us 36

Disclaimer 37

List of Tables

List of Tables

Number of Products under Development for Ragweed Allergy, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Comparative Analysis by Unknown Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Ragweed Allergy – Pipeline by Anergis SA, H2 2016 13

Ragweed Allergy – Pipeline by Biomay AG, H2 2016 14

Ragweed Allergy – Pipeline by Circassia Pharmaceuticals Plc, H2 2016 15

Ragweed Allergy – Pipeline by Immunomic Therapeutics, Inc., H2 2016 16

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Stage and Target, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Ragweed Allergy – Dormant Projects, H2 2016 30

Ragweed Allergy – Discontinued Products, H2 2016 31

List of Figures

List of Figures

Number of Products under Development for Ragweed Allergy, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Types, H2 2016 21


Discounts available for multiple report purchases.

+44 (0) 161 359 5414

Saved reports